Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.
Invernizzi PietroMarco CarboneDavid JonesCynthia LevyNicola LittlePhilippe WieselFrederik Nevensnull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
The primary endpoint was not met. However, the secondary endpoints provide preliminary evidence for potential anti-cholestatic and anti-fibrotic effects in PBC, supporting the further evaluation of setanaxib in a future phase 2b/3 trial.